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Abstract: Despite the amount of resources deployed and the technological advancements in molecular
biology, vaccinology, immunology, genetics, and biotechnology, there are still no effective vaccines
against malaria. Immunity to malaria is usually seen to be species- and/or strain-specific. However,
there is a growing body of evidence suggesting the possibility of the existence of cross-strain,
cross-species, and cross-genus immune responses in apicomplexans. The principle of gene
conservation indicates that homologues play a similar role in closely related organisms. The homologue
of UB05 in Theileria parva is TpUB05 (XP_763711.1), which has been tested and shown to be associated
with protective immunity in East Coast fever. In a bid to identify potent markers of protective
immunity to aid malaria vaccine development, TpUB05 was tested in malaria caused by Plasmodium
falciparum. It was observed that TpUB05 was better at detecting antigen-specific antibodies in plasma
compared to UB05 when tested by ELISA. The total IgG raised against TpUB05 was able to block
parasitic growth in vitro more effectively than that raised against UB05. However, there was no
significant difference between the two study antigens in recalling peripheral blood mononuclear cell
(PBMC) memory through IFN-γ production. This study suggests, for the first time, that TpUB05
from T. parva cross-reacts with UB05 from P. falciparum and is a marker of protective immunity in
malaria. Hence, TpUB05 should be considered for possible development as a potential subunit
vaccine candidate against malaria.
Keywords: Malaria vaccine development; UB05; TpUB05; marker of protective immunity;
homologues; cross-species protective immunity
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1. Introduction
The malaria parasite has a complex life cycle, consisting of developmental stages in the liver
(sporozoites) and blood (merozoites, trophozoites, and schizonts) of vertebrates and Anopheles
mosquitos (male and female gametocytes), which serve as transmission vectors [1]. Antigens in the
blood-stage of malaria parasites represent targets of parasitic growth and replication, which provoke
immune responses that either exacerbate or prevent the growth and development of the parasites in
the vertebrate host, hence affecting disease outcomes [2].
Clinical manifestations of malaria are attributed to the blood-stage of parasites that reside within
red blood cells (RBCs); thus, vaccines developed against erythrocytic forms of the parasite may
contribute considerably to the efficient control of the disease. There are now a number of blood-stage
antigens that are being characterized for inclusion as vaccine components in clinical development [3].
Amongst the most studied and advanced blood-stage vaccine antigens, these include circumsporozoite
protein (CSP), serine repeat antigen 5 (SERA-5), merozoite surface protein 3 (MSP-3), and apical
membrane antigen 1 (AMA1) [3]. These vaccine candidates have not been efficacious in African
children [4,5]. However, a multistage vaccine made up of CSP and AMA1 has reduced the incidence
of clinical malaria episodes in vaccinated children by 50% compared to a control group [6]. RTS,S
(Mosquirix™), a leading vaccine candidate that targets the initial infection of the liver, has only
demonstrated a partial efficacy that wanes rapidly [7]. Although a number of erythrocyte-stage
antigens are under development, there is still a need to search for better markers of protective immunity
and hence, subunit vaccine candidates to improve vaccination outcomes. Second-generation vaccine
candidates that could constitute a multivalent rather than univalent vaccine candidate are required,
where they could target red-blood-cell-stages and other stages of the parasite [8]. There is, therefore, a
need to search other vaccine candidates for the development of a successful malaria vaccine that can
confer both full and long-lasting protection.
One approach of identifying better markers of protective immunity would be to seek homologues
of markers of protective immunity in closely related organisms. The idea of the conservation of
gene products has been proven to suggest that orthologous gene products appear to perform similar
functions in closely related species [9]. For example, a circumsporozoite protein (CSP)-based vaccine
(VMP001) from Plasmodium vivax, containing conserved CSP regions, generated antibodies that could
also recognize CSP on the surface of P. berghei and P. falciparum. Antibodies provoked in mice by
recombinant PfCelTOS induced cross-species protection against P. berghei challenge by cross-reactivity
to heterologous P. berghei sporozoites [10]. With the knowledge that homologues may play similar roles
in closely related organisms, the information obtained by studying markers of protective immunity
could be transferred to another antigen or disease. Conceivably, the homologue of UB05 in Theileria
parva, TpUB05, has also been shown to be a marker of protective immunity in East Coast Fever (ECF)
that affects cattle [11].
In previous studies from our group, the P. falciparum antigens UB05, UB09, and chimeric UB05-09
and their respective polyclonal antiserums were analyzed using ELISA, ELISpot assays, and growth
inhibition assays with samples from a malaria endemic region. These findings have been published
in [12–14]. During these same studies, we included TpUB05 and its polyclonal antiserum in separate
wells on the same plates and exposed them to the same experimental conditions as the UB05 antigen.
In this paper, we present the obtained data and compare the performance of the UB05 antigen from
P. falciparum as a control antigen to that of TpUB05 from T. parva in human malaria.
2. Results
2.1. Molecular Cloning and Characterization of TpUB05
Using gene-specific primers, TpUB05 was amplified from T. parva schizont RNA using reverse
transcription to produce a 291 bp DNA fragment [11], while UB05 was amplified from a P. falciparum
cDNA library to produce a 243 bp DNA fragment [12]. Both fragments were cloned into a pET32a+
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expression vector and overexpressed in Escherichia coli cells, yielding recombinant fusion proteins
migrating at 28 KDa and 26 KDa, respectively, in SDS-PAGE performed in 15% polyacrylamide.
The recombinant fusion proteins contained a 6xHis tag, a S tag domain, and a 109 amino acid
thioredoxin fusion protein partner. However, it was easier to overexpress and purify TpUB05 as
compared to UB05.
2.2. TpUB05 Antigen from T. parva Possesses B-Cell Epitopes that Cross-Reacted with Human Antibodies in a
Malaria Endemic Area
Forty (40) semi-immune status (SIS), 34 frequently sick status (FSS), and 27 sick children (SC)
samples were obtained; thus 101 samples were analyzed using ELISA. Plasma from the study subjects
was tested with TpUB05 using ELISA and it was shown that SIS possessed greater amounts of antibodies
compared to FSS. However, the difference was not observed to be statistically significant using analysis
of variance (ANOVA) and Friedman tests. Adults (SIS + FSS) produced (average optical density (OD)
value of 0.372) 3.62 times more antigen-specific antibodies to TpUB05 (p = 0.0001) than children (SC;
average OD value of 0.102; Figure 1A).
There was a statistically significant difference between TpUB05 and UB05 for all 101 subjects (SIS,
FSS, and SC; paired samples t-test) and for the 74 adults (SIS and FSS; Wilcoxon signed rank test). Both
tests gave a p-value of 0.006 (Figure 1A,B).
However, looking at the average OD values obtained for SIS (0.39 for TpUB05 and 0.37 for UB05)
and FSS (0.34 for TpUB05 and 0.31 for UB05), the difference, which is statistically significant, does not
appear to be biologically significant; however, the data suggest cross-reaction (Figure 1B).
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Figure 1. Antibody response of TpUB05 in humans. (A) Comparison of antigen-specific antibodies to
TpUB05 in plasma collected from human subjects (semi-immune status (SIS), frequently sick status
(FSS), and sick children (SC)). Plasma fro SIS (40 subjects) contained more TpUB05-specific antibodies
compared to FSS and SC (61 subjects; p = 0.0001 using analysis of variance (ANOVA)). Bars represent
the mean optical density (OD)405 value. (B) Average OD405 values of TpUB05 and UB05 were observed
with the different immune status groups. The data show that t ere is no biological difference between
anti-TpUB05 and anti-UB05 antibodies levels ev n though the p-value indicates otherwise. Error bars
represent standa d deviation.
2.3. Human Antibody Levels to TpUB05 Negatively Correlate with Fever and Malaria Parasitemia
When the antibody levels to TpUB05 were plotted as a function of parasitemia, it was observed
that that there was a negative correlation bet een parasitemia and antibody levels. This implies
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that the higher the specific antibody level, the lower the parasite density in the blood. In other
experiments, antibody levels have been shown to be statistically higher in subjects without a fever
than in subjects with a fever (Figure 2A,B). With r = −0.393 and a significant p-value of 0.0001, there is
a significant negative correlation between TpUB05-specific antibody levels and parasite load. What is
driving this result is the one subject presenting 20 × 104 parasitemia and the four subjects presenting
around 5–10 × 104 parasitemia. If those subjects are removed from the analyses, the correlation would
disappear. Taken together, these results suggest that the responses to the two antigens are very similar.
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Figure 2. Relation between fever, parasitemia, and antibody response to TpUB05. (A) Comparing
the absence or presence of fever with the anti-TpUB05 antibody level in human plasma (p = 0.0001).
Subjects without fever had significantly higher levels of antigen-specific antibodies than those with fever.
This significant difference was determined using ANOVA. (B) The relationship between anti-TpUB05
antibody levels and parasite load indicates there is a negative correlation (r = −0.393, p = 0.001). Pearson
correlation was used to analyze the correlation.
2.4. Tpub05 Stimulates T-Cell Responses of Semi-Immune Malaria Patients Greater than Those of Malaria
Susceptible Patients
In an attempt to investigate the possible ability of TpUB05 in T-cell mediated immunity we
compared the T-cell responses of co orts of semi-immune and susceptible malaria patients to these
orthologous antigens. Sixty-three (63; c nsisting of 35 SIS and 28 FSS) eripher l blood mo onuclear
cell (PBMC) s mples were used for a human ELISpot assay. More PBMCs from SIS produced IFN-γ
than FSS when stimulat d with the TpUB05 antigen (p = 0.0001 using t-test; Figure 3A). When the
recognition of TpUB05 was compared to that of UB05 (Figure 3B), there was no si nificant difference
(Figure 3C).
The determination of spot-forming cells per million (SFC/106 cells) was also used to assess the
difference between TpUB05 and UB05 in recalling T-cell fu ction by IFN-γ producti n. The magnitude
of the response showed TpUB05 provokes more cells from SIS (average f 168 SFC/106 cells) to produce
IFN-γ than FSS (average of 40 SFC/106 cells). The same trend was observed for UB05 (average of
166 SFC/106 cells for SIS and 49 FC/106 cells for FSS; Figure 3A–C). The positive controls had values
ranging fr m 6993 to 8476 SFC/106 cells (data not shown).
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Using stimulatory index (SI), we also found significantly higher IFN-γ production by PBMCs
from subjects with no fever (p = 0.002) compared to those who had a fever (Figure 4A). The same trend
was observed when the SI values were compared to the absence or presence of parasitemia. (Figure 4B).
These results suggest that TpUB05 is a marker for protective immunity to malaria due to preferential
stimulation of the production of IFN-γ in SIS.
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Figure 4. Relationship bet een T-cell responses (IF -γ production) to reco binant TpUB05, fever,
and parasitemia. (A) Subjects with no fever (SIS) appear to produce more IFN-gamma in response to
stimulation by TpUB05 compared to those with a fever (FSS; p = 0.002 using ANOVA). Bars represent
mean values. (B) Production of IFN-gamma is associated with a protective immune response against
malaria amongst these adults. Pearson correlation analysis showed r = −0.295, p = 0.01.
2.5. Rabbit Polyclonal Antibodies Raised against Recombinant TpUB05 Perform Better in Inhibiting P.
falciparum Parasite Growth in Vitro than Antibodies to Recombinant UB05
The ability of the TpUB05-specific antiserum to inhibit parasite growth in vitro was tested using
a growth-inhibition assay (GIA), as described in the Materials and Methods section, and the data
were compared with those obtained with the UB05-specific antiserum. Rabbit anti-TpUB05 antiserum
was able to inhibit parasite growth in vitro significantly better than the performance of the anti-UB05
antiserum (p = 0.0001 using ANOVA; Figure 5). This inhibition was observed for all the parasite strains
tested (Figure 5).
In the positive control experiments, we tested in parallel two monoclonal antibodies available
from BEI Resources, namely, anti-AMA1 and anti-EBAI1. Amongst the parasite strains tested, only the
P. falciparum HB3 strain was not inhibited by the positive control monoclonal antibodies (anti-AMA1
and anti-EBA175), indicating that these two are less cross-reactive than those directed against TpUB05
and UB05. The results presented in Figure 5 show that anti-TpUB05 antiserum does not inhibit
parasite growth significantly more than anti-AMA1 antibody. However, it performed better than the
anti-EBA175 antibody in inhibiting in vitro parasite growth (p = 0.0001 using ANOVA).
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Figure 5. Comparing anti-TpUB05 and anti- B05 polyclonal antiserum in a growth-inhibition assay.
Rabbit antisera against rTpUB05 and rUB05 were used in vitro to test for their ability to inhibit parasite
growth. The anti-TpUB05 antiserum performed better than anti-UB05 antiserum in inhibiting in vitro
parasite growth (p = 0.0001 using ANOVA). This was done using P. falciparum laboratory strains, 3D7,
FCR-1/FV0, and HB3, and two field isolates, GH01 and SC01. They were tested at a 1:10 dilution.
The experiment was run in triplicate and repeated once. Error bars represent standard deviations.
2.6. Online Biometric Prediction Indicates the Presence of TpUB05 Epitopes Capable of Binding to Human
Major Histocompatib lity Complex (MHC) Epitopes
The online prediction of human T-cell and antibody epitopes revealed the presence of epitopes
that could bind to human MHC on TpUB05. MHC I and II binding peptides with a percent le rank
below 1.0 were considered as those with a very high affinity for the MHC molecules (Supplementary
Ta le S1). The lower the percentile rank, the stronger the binding affinity. Using algorithms from
www.iedb.org, we also predicted the presence of human antibody epitopes in TpUB05 (Supplementary
Table S1).
3. Discussion
Malaria subunit vaccine development has mostly focused on single antigens. However, the
complex nature of the malaria parasite life cycle and the mechanisms it uses to evade human immune
response implies the ideal malaria vaccine should target several antigens expressed at different stages
of the parasite’s development [8], as well as homologous antigens from related species. Such a vaccine
would circumvent the setbacks observed with strain-specific or species-specific protective immune
responses. The first step towards this would be the identification and characterization of homologous
antigens from phylogenetically related organisms as markers of protective immunity against malaria.
Here, we have shown for the first time that the TpUB05 antigen from T. parva cross-reacts with UB05
and is associated with protective immunity in malaria.
The UB05 antigen has previously been compared to its chimeric construct, UB05-09, using an
ELISpot assay, ELISA, and growth-inhibition assay, published in [12–15], respectively. During those
experiments, TpUB05 was added into separate wells on the same plates and exposed to the same
experimental conditions as the other study antigens/antisera. However, the results of these experiments
on TpUB05 are only reported in the present paper. Since the data on UB05 have previously been
published, we are now using them as control data to compare the provoked and detected immune
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responses to those provoked or detected by its homologue in T. parva, TpUB05. From all samples from
which PBMCs were isolated, plasma was also collected for ELISA, but not all ELISA samples were
collected from samples from which PBMCs were isolated. Hence, more samples were analyzed using
ELISA than ELISpot assays.
The principle of the conservation of gene functions shows that most orthologous gene products
play a similar role in closely related organisms [9]. We decided to characterize TpUB05 in malaria
caused by P. falciparum. This observation of effective cross-immunization with homologous antigens
has been shown previously [9]. In other words, it might be more useful to search for antigens that
induce protection against ECF and test malaria caused by a distant relative, such as P. falciparum. To
verify this hypothesis, we carried out the simultaneous testing of immune responses in semi-immune
and malaria-susceptible subjects and found that the TpUB05 antigen from T. parva cross-reacts with the
UB05 antigen from P. falciparum.
Although B-cells have been seen to contribute little to resistance and protective immunity for
infections with apicomplexans, many studies have shown that hosts infected with these parasites
are capable of producing parasite-specific immunoglobulins which are protective after recovering
from an infection [16]. The present study shows that antibodies in human plasma recognized
TpUB05. The significant p-values obtained when antibody levels/magnitude of IFN-γ production were
compared to fever status, as well as the significant negative correlation observed between antibody
levels/magnitude of IFN-γ production and parasitemia, indicate that immune responses to TpUB05 are
associated with protection against malaria caused by P. falciparum.
Studies to elucidate the mechanism(s) of the protective immune response to apicomplexan
parasites implicate the role of the production of gamma interferon (IFN-γ), amongst other cytokines
and chemokines [17], which control parasite infectivity and interfere with parasite development.
Biostatistical analyses have revealed that there are T-cell epitopes in TpUB05 that could bind and be
recognized by human T-cells, leading to the production of IFN-gamma. This production of IFN-gamma
occurs in a manner that is associated to immune protection against malaria, as it is preferentially
recognized by semi-immune subjects compared to frequently sick subjects. The significant p-values
obtained when magnitudes of IFN-γ production were compared to fever status, as well as the significant
negative correlation observed between magnitude of IFN-γ production and parasitemia, indicate that
immune responses to TpUB05 are associated with protection against malaria. When these data were
compared to those obtained with the UB05 antigen from P. falciparum [12], which were obtained under
the same experimental conditions, the same trend of correlation with protection against malaria was
observed. There was no significant difference between these two antigens in stimulating the production
of IFN-gamma from human PBMCs, suggesting that they could stimulate similar reactions in vivo;
however, this remains to be shown.
The hallmark of an effective malaria subunit vaccine would be its ability to stimulate the cellular
and antibody components of the immune system that are protective. This implies that an antigen’s
ability to preferentially detect antigen-specific antibodies and recall T-cell function in people who have
acquired limited protective immunity to malaria is an indication that the protein is involved in immune
protection against malaria parasites. TpUB05 was able to recall T-cell ability to produce IFN-gamma
in SIS subjects and detect antigen-specific antibodies in these subjects, hence, it is associated with
protective immunity in malaria.
A normal body temperature with little or no parasites in the blood, as well as higher IFN-gamma
production and antibody amounts, have been shown to correlate with immune protection against
clinical malaria [18–20]. The data obtained in this study strongly suggest that TpUB05 is associated
with protective immunity in clinical malaria.
The contamination of antigen preparations with lipopolysaccharide (LPS) has been shown to
confound T-cell response assay results to malaria antigens. However, it is unlikely that there was a
contribution of possible contaminating bacterial LPS to the observed responses in the present study,
as the responses were specific to each of the groups and as the control antigen (UB05) was prepared
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under similar conditions and treated in the same way as the test antigen (TpUB05). Cytokines whose
production appear to be influenced by LPS include IL-1beta and IL-6. However, IFN-gamma, whose
production is not affected by LPS, was studied herein [21].
The present study shows that TpUB05 possesses T-cell and B-cell epitopes that bind and recognize
human MHC molecules and antibodies, respectively. This was confirmed using in silico algorithms.
It was then necessary to determine if the polyclonal antibodies raised against TpUB05 from T. parva
have any effect on malaria parasite development by employing an in vitro growth-inhibition assay.
The growth-inhibition assay, which involves impaired merozoite invasion and the subsequent
development of parasites in erythrocytes, is currently being considered as one of most relevant
assays to screen potential blood-stage vaccine candidates prior to moving to the stage of clinical
development. Purified polyclonal total IgG induced in rabbits against TpUB05 from T. parva was able
to significantly inhibit malaria parasite growth in vitro. This inhibition was statistically higher than
that observed with the anti-UB05 polyclonal antibody as well as the anti-EBA175 monoclonal antibody,
but not the anti-AMA1 monoclonal antibody. Hence, TpUB05 should be considered to be associated
with protective immunity against malaria.
A bioinformatics comparison of TpUB05 and UB05 shows that they exhibit a degree of sequence
homology, where 43.3% identity and 67% similarity was observed. The in silico analysis predicted
the presence of human T-cell and antibody epitopes of TpUB05 and the cross-reactivity observed was
expected, in view of the significant homology between the two antigens. However, TpUB05 may
contain more potent B-cell epitopes compared to UB05 that are yet to be identified.
Altogether, the results from this study imply that TpUB05 is associated with protection against
malaria, and this confirms the notion that homologues could play similar roles in related organisms.
This is in line with previous studies where Mycobacterium bovis (BCG vaccine) was used to vaccinate
humans against M. tuberculosis [22] and where humans exposed to Onchocerca ochengi were protected
against O. volvulus infection [23]. The potential role of TpUB05 in inducing an effective immune
protection against malaria infection and disease warrants more investigation.
The importance of immune cross-reactivity may indicate the enhancement of protective immune
responses amongst distantly related apicomplexans such as P. falciparum and T. parva. There is a strong
cross-reactivity between TpUB05 and UB05 antigens, based on ELISA, ELISpot, and growth-inhibition
data, strongly suggesting the use of TpUB05 for the development of a malaria vaccine.
4. Materials and Methods
4.1. Study Site and Design
The study was carried out in Buea, which is an endemic center for malaria. Buea is a multi-ethnic
town found along the flanks of Mount Cameroon in the southwestern region of the Republic of
Cameroon. The prevalence of malaria in Buea varies between meso-endemic (dry season) and
hyperendemic (rainy season) zones with perennial malaria transmission [24].
The UB05 antigen has previously been tested and compared to its chimeric construct, UB05-09 and
published [12,14,15]. During those experiments, the TpUB05 antigen was added into separate wells on
the same plates and exposed to the same experimental conditions as the other study antigens/antisera.
However, the data obtained with TpUB05 are only reported in the present paper. We are now using the
data on UB05 as control data since it has already been published. So the immune responses detected
by UB05 is being compared to those provoked by its homologue in T. parva: TpUB05 (Table 1).
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Table 1. Study design to show how the study was planned, executed, and reported.
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The following criteria were used to screen and recruit subjects into the study, as earlier published:
(i) Subjects who were aged 18 years of age or older and who had been living in the study site for at
least 3 years; (ii) subjects with no history of a malaria episode in the last 12 months, no fever, and
parasitemia at sample collection, no use of a mosquito bed net, hence being exposed to mosquito
bites, nd no prophylaxis were designated to semi-i mune subjects (SIS); (iii) subjects who had had at
least one alaria p sode in the last 12 months and had a fever an parasitemia at the time of sample
collectio were referred to as frequently sick subjects (FSS); and (iv) children aged five or younger who
had a fever and parasitemia at the time of sample collection were referred to as sick children (SC). This
cohort of individuals was highly selective and has been described previously [12,16]. The analyses
for fever, parasitemia, and blood sample collection for ELISpot assay and ELISA took place between
March and June of 2014 [12].
4.3. Assessment of Nutritio al Status
It has been shown that being in good health reduces susceptibility to non-communicable and
infectious diseases, including malaria [25]. The assessment of the nutritional status of the study
population was done, as it is assume that a probable indication of good health and being healthy is
having a normal body mass index (BMI) [26]. Only subjects in the nor al or pre-obese range were
admitted into the study [12,27]. Underweight or obese persons were excluded in the study. BMI was
calculated by the following formula: BMI (kg/m2) = weight (kg)/height2 (m)
4.4. Parasite Strains, Antigens, and Polyclonal Antibody
As previously mentioned [15], all laboratory strains were generously donated by the MR4/BEI
Resources, NIAID, NIH, Manassas, VA. The following P. falciparum laboratory strains were used:
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FCR-1/FVO (MRA-909, contributed by W. Trager), 3D7 (MRA-102, contributed by Daniel J. Carucci),
and HB3 (MRA-155, contributed by Thomas E. Wellems) for the in vitro assay. Two field isolates,
GH01 and SC01, were also used for the study, and were obtained from the Buea District Hospital and
Solidarity Clinic, Buea, Cameroon, respectively. The overexpression of recombinant TpUB05 and its
polyclonal antibody production in rabbits has been previously described [11].
4.5. Preparation of Peripheral Blood Mononuclear Cells from Human Donors
The procedure to isolate peripheral blood mononuclear cells (PBMCs) was performed according
to manufacturer’s instructions. Briefly, the preparation of PBMCs for use in the ELISpot assay was
done using the Percoll gradient method, as earlier described [28]. Briefly, 8 mL of venous blood was
collected from subjects in EDTA-containing tubes. An equal volume of sterile PBS was then added
to the blood samples and layered on a Percoll discontinuous gradient solution (5 mL each of 60%,
50%, and 40% Percoll solution, layered in that order). The samples were centrifuged at 11,709 × g for
30 min. The white buffy coats at the 40%/50% and the 50%/60% interfaces were carefully collected
and put into a 50 mL falcon tube. These interfaces contain monocytes and lymphocytes, respectively.
Washing of the collected buffy coats to remove excess Percoll was done twice with 40 mL of sterile PBS
supplemented with 5% fetal calf serum at 4000 rpm for 10 min. Cells were then re-suspended in 2 mL
of complete R.P.MI-1640 culture medium (CCM), and cell viability and quantification was done using
Trypan blue staining and an improved Neubauer counting chamber [29].
4.6. Enzyme-Linked Immunosorbent Spot (ELISpot) Assay
The enzyme-linked immunosorbent spot assay was carried out as described [12]. Briefly, the
ELISpot assay was used to determine the proportion of IFN-gamma-secreting PBMCs from subjects ex
vivo upon stimulation with recombinant antigens TpUB05 and UB05. The PBMCs were used within
2 h of collection in EDTA-containing tubes, that is, they were transported to the laboratory (10 min
away), isolated, and analyzed. Cell and antigen preparations were carried out in a biological safety
cabinet prior to use to ensure the sterility of the cells and protein samples. Here, 5 µg/mL of each
antigen was mixed with 300,000 PBMCs and tested in triplicate. MABTECH AB kits were used to
carry out the ELISpot assay, as previously described [27]. The positive control used to recall T-cell
memory was the anti-CD3-2 monoclonal antibody. Negative controls were wells with PBMCs and PBS
only (no antigen). The stimulation index (SI) was calculated as follows: SI = mean number of spots
in triplicate test (with antigen) wells divided by mean number of spots in triplicate negative control
(without antigen) wells. An SI value of more than two was considered positive [30,31]. SFC/106 cells
were also used to determine the magnitude of response by PBMCs. The antigen-specific spots count
was calculated as the mean of three wells minus the mean spot count from PBS negative control wells.
Spot counts were multiplied by 3.33 to obtain spot-forming cells per million cultured PBMCs. All
analyses were performed with these final counts, i.e., spots forming cells per million cultured PBMCs.
4.7. Plasma Sample Collection
Plasma was collected from the blood samples and stored until further analysis. At the time of
performing the ELISA experiments, additional subjects were recruited into the study to obtain more
plasma samples and increase the sample size for analysis. Plasma samples were also collected in EDTA
tubes from children below the age of five whose parents gave their consent and tested positive for
malaria (fever and parasitemia). The samples were then centrifuged and the plasma was aspirated and
stored at −20 ◦C until use.
4.8. Determination of the Levels of Antibodies Recognizing r-TpUB05 and r-UB05 By ELISA
Antibody (total IgG) measurement was carried out by ELISA, as earlier described [32], with some
modifications. Here, we used 100 µL of 0.625 µg/mL r-TpUB05 or r-UB05 in PBS, which was used to
coat microtiter plates by incubation at 4 ◦C overnight. Some wells were coated with a soluble fraction
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of crude E. coli extract or the r-UB05 antigen as a positive control for the antigen, while the tag-only
(Fusion partner) antigen was used as a negative control antigen. The plates were washed thrice with
200 µL of a wash buffer (PBS-Tween-20, 0.05%) after overnight incubation, followed by blocking with
150 µL per well of 0.2% casein in PBS with 0.05% Tween-20. After the second washing, plasma was
added at 1:150 dilutions in the wash buffer, containing 1% skimmed milk. The samples were then
incubated at room temperature for 3 h. To obtain and record background signals (negative control
for plasma), human plasma from malaria-naïve individuals, which was kindly given to us by Mrs.
Philomena Gwanmesia of the Biotechnology Center, University of Yaounde I, Cameroon, was included
in the assay. After the 3 h incubation at room temperature, the plates were washed with the wash buffer
three times and 100 µL of the anti-rabbit IgG-HR.P. conjugate was diluted at 1:10,000 in a wash buffer
containing 1% skimmed milk and then incubated for 1 h at room temperature, after which the plates
were washed with the wash buffer and 100 µL of the substrate added. The optical densities (OD) of the
wells were obtained at 405 nm using a microplate reader. A subject was considered positive if its OD
value was equal to or greater than the mean control OD + 2 Standard Deviation (2SD). The experiment
was run in duplicate.
4.9. Growth Inhibition Assay
The ability of purified rabbit IgGs induced against r-TpUB05 and r-UB05 to inhibit the replication
of P. falciparum in vitro was tested by measuring parasite lactate dehydrogenase (pLDH) in the late
trophozoite- /early schizont-stages in cultures, as described in Methods In Malaria Research 6th
Edition [33]. Briefly, the enrichment of late-stage infected erythrocytes was done by performing three
5% sorbitol synchronizations and 60% Percoll gradient centrifugations. The assay was performed using
late trophozoite- or schizont-stages. This was ensured by starting and stopping (at approximately 96 h)
the experiment when most of the parasites were at those stages. The start parasitemia of the culture
was kept at 0.1%–0.3% parasitemia and 1% hematocrit in a CO2 incubator for two cycles. Polyclonal
antibodies raised against r-TpUB05 or r-UB05 were added at the start of the cultured at an optimized
dilution of 1:10 (final concentration of anti-TpUB05 total IgG = 0.48 mg/mL and anti-UB05 total IgG
= 0.63 mg/mL). The monoclonal antibodies, anti-EBA-175 RII (final concentrations; R217 at 0.133
mg/mL and R218 at 0.153 mg/mL), and anti-AMA1 (final concentration of 0.1 mg/mL), were used as
positive controls in the inhibition assays, while the negative control wells contained pre-immune sera
(final concentration of 0.7 mg/mL) or no antiserum. The control wells were included in the assay that
contained either only parasitized RBCs (pRBC only) or normal RBCs. Percentage growth inhibition
was calculated by subtracting the average OD from the normal RBCs wells from all the other OD
values obtained before proceeding to the calculation proper.
4.10. Immune Epitope Prediction using Online Resources
The in silico prediction of immune epitopes from TpUB05 and UB05 was done using algorithms
from IEDB Analysis Resources (www.immuneepitope.org). The MHC I binding predictions were made
on 7/30/2019 using the IEDB recommended method, which combines predictions from ANN [34–37],
SMM [38], and Comblib [39]. The MHC II binding predictions were made on 7/30/2019 using the
IEDB analysis resource consensus tool [40]. The Emini surface accessibility scale [41], Kolaskar and
Tongaonkar antigenicity scale [42], BepiPred-1.0 linear epitope prediction [43], and BepiPred-2.0
sequential B-cell epitope predictor [44] were used to predict the presence of human antibody epitopes
on TpUB05.
4.11. Statistical Analysis
The analysis of variance test was employed to compare differences between the mean OD and SI
values between study groups. The Kruskal–Wallis test was used to assess differences between the body
temperature, parasitemia, OD, and SI values. All these tests were performed using the SPSS software
(Version 17.0, Chicago, IL, USA). A value of p < 0.05 was considered significant.
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4.12. Ethics Approval and Consent to Participate
Ethical clearance for this study (Ref.: 2013/144/UB/FHS/IRB) was obtained from the Institutional
Review Board of the Faculty of Health Sciences, University of Buea. All participating adult subjects
read, approved, and signed the consent form. A parent or guardian of any child participating in the
study provided informed consent on the child’s behalf. The informed consent given was written.
Ethical clearance for blood collection and polyclonal antibody production in rabbits was approved
by the International Livestock Research Institute—Institutional Animal Care and Use Committee
(ILRI-IACUC; ref. no. 2013.05). ILRI-IACUC provided clearances based on “The Animal Research:
Reporting In Vivo Experiments” (ARRIVE) guidelines on the care and use of animals in research.
Supplementary Materials: The following are available online at http://www.mdpi.com/2076-0817/9/4/271/s1,
Table S1: Predicted human T-cell and B-cell epitopes predicted on TpUB05 antigen Immune epitopes on the
TpUB05 antigen were predicted in silico using algorithms found on www.iedb.org. MHC I and II binding peptides
presented here are those with a percentile rank below 1.0. Percentile rank below 1.0 were considered as those with
a very high affinity for the MHC molecules. The lower the percentile rank the stronger the binding affinity. These
would have to be tested in vitro and in vivo to confirm their immunogenicity.
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